Acquiring a new company or product line can come with regulatory and quality challenges. RQM+ experts have extensive hands-on regulatory, quality, clinical, and reimbursement experience, and can provide a comprehensive due diligence assessment and implement an integration plan. We also have the resources and experience to plan and implement an M&A integration following a deal.
Many factors go into the decision to acquire a company or product line. Understanding the risks and challenges associated with the acquisition allows you to plan accordingly. Whether you plan to market the device in Europe, the United States, or elsewhere, our seasoned team can provide a comprehensive assessment of the company's:
RQM+ can help develop and implement business balanced regulatory, quality, reimbursement, and clinical integration plans that address compliance issues and streamline the integration.
As a strategic partner, we provide more than just as-needed support for regulatory and quality tasks. Industry veterans who have a deep understanding of the evolving regulatory landscape provide critical insights and a risk-balanced approach for focusing your acquisition efforts with your entire portfolio and business goals in mind.
RQM+ can help manage, develop, and implement integration plans using our team of highly skilled resources to ensure compliance and maintain a seamless workflow. We can also help update regulatory submissions and generate clinical data by designing and executing clinical trials or surveys.
When your internal teams are taxed during a major acquisition, RQM+ can help in whatever capacity you need. Whether you need us to handle all QA/RA related to the acquisition so your team can continue with daily activities, or you need us to support sustaining and product development so your team can focus on the acquisition, we have you covered.
RQM+ can perform on-going integration/remediation support and effectiveness checks, as well as mock FDA audits or notified body reviews, to determine what is needed after an integration to ensure our clients teams are ready for the future and positioned for sustained growth.
In my experience, I have seen significant liabilities inherited during company acquisitions due to unplanned regulatory compliance issues. Regulations are constantly changing. In Europe, the burden and cost of compliance has risen considerably over the years. Just because a product has been cleared, approved or certified, with a long history on the market is not an adequate rationale that no liability risk exists, or additional effort is required to maintain keeping these products on the market.
"Due diligence activities should cover all applicable regulatory requirements of the firm based on the company’s role and the type of medical devices on the market given the geographical region in which they are marketed. Diligence should include a review of the status of registrations, listings, licenses, and planned or pending submissions requiring regulatory agency involvement or approval. A review of product labeling and advertising to ensure all claims are consistent for the approved intended use to mitigate potential risks of misbranding and enforcement actions.
Assessment activities should include a review of established quality system procedures, staff training, design and production histories, critical suppliers, device and process validations, technical files, submissions, and status of certifications. A review of audits, disciplinary measures and corrective action plans provide insight into the effectiveness of the quality management system and commitment of the executive management team."
Potential areas of concern include ‘letters to file’ that should have required a regulatory submission or involvement of a regulatory body. Product issues in the field that were not handled properly as complaints, such as thorough investigations, impact/ risk assessments, corrections/ removals, and reporting to regulatory authorities. The lack of robust product technical files and design history file documentation is a common issue. Without solid supporting design documentation, it is extremely challenging to justify design changes, such as changes in materials, manufacturing processes, or the supplier base. If the acquisition of the company is being driven by a specific product portfolio, you should be prepared to do a deep dive into the technical files or 510K or PMA, the clinical evaluation, any critical contractors or suppliers, the type of complaints received, any CAPA’s that have opened, and issues that have been escalated.
GLOBAL BOTTOM CTA INSTRUCTIONS:
To display custom copy instead of global copy in this section, please go to Show Global Content for Bottom CTA? toggle in the "Contents" tab to the left, toggle it off, save, and then REFRESH the page editor, the custom text will then show up and ready to be edited.
Turning the global content back on will be the same process, go to the toggle and toggle it back on, save and refresh!
United States HQ 2790 Mosside Blvd. United States (U.S.) |
Europe HQ 3rd Floor, 1 Ashley Road Altrincham, Cheshire, |
©2024 RQM+ All Rights Reserved | Privacy Policy | Cookies Policy